Tiny RXi bags an op­tion to buy CAR-T fledg­ling Mir­Im­mune

Eigh­teen months af­ter Mir­Im­mune grabbed a li­cense to RXi’s $RXII RNA tech for use in de­vel­op­ing new cell ther­a­pies, the tiny moth­er ship — with a mar­ket cap of on­ly $11 mil­lion af­ter a steady fade of its stock price — is now look­ing to reel back the whole ef­fort un­der a buy­out op­tion.

Based in Marl­bor­ough, MA with a group of co-founders that in­cludes the for­mer CEO of Sepra­cor, Tim Bar­berich, the low-pro­file Mir­Im­mune went to RXi last March to gain a li­cense to a tech that could be used to de­vel­op new cell im­munother­a­pies for can­cer — a hot top­ic in the biotech world. Ini­tial­ly, RXi had re­served an op­tion for a chunk of Mir­Im­mune.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.